Manufacturer of Controlled Substances; Notice of Application, 55588 [E9-26002]

Download as PDF 55588 Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices Dated: October 16, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25895 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 9, 2009, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342–4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: erowe on DSK5CLS3C1PROD with NOTICES Drug Schedule Gamma Hydroxybutyric Acid (2010). Methaqualone (2565) ................... Ibogaine (7260) ............................ Tetrahydrocannabinols (7370) ..... 2,5-Dimethoxyamphetamine (7396). Psilocyn (7438) ............................. Normorphine (9313) ..................... Acetylmethadol (9601) ................. Alphacetylmethadol except levoalphacetylmethadol (9603). Normethadone (9635) .................. Norpipanone (9636) ..................... 3-Methylfentanyl (9813) ................ Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Phenylacetone (8501) .................. 1-Piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Isomethadone (9226) ................... Meperidine (9230) ........................ Meperidine intermediate-A (9232) Meperidine intermediate-B (9233) Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk, (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. VerDate Nov<24>2008 15:34 Oct 27, 2009 I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II Jkt 220001 Drug Schedule Oxymorphone (9652) ................... II The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009. Dated: October 20, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25893 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 10, 2009, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Difenoxin (9168) ........................... Propiram (9649) ........................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Nabilone (7379) ............................ Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 I I I I I II II II II II II II II II II II II Drug Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a controlled substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009. Dated: October 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–26002 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 15, 2009, and published in the Federal Register on June 23, 2009, (74 FR 29720), Noramco Inc., Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II. The company plans to bulk manufacture the above listed controlled substance for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at E:\FR\FM\28OCN1.SGM 28OCN1

Agencies

[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Page 55588]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26002]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 10, 2009, Johnson 
Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West 
Deptford, New Jersey 08066-1742, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Difenoxin (9168)...........................  I
Propiram (9649)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a controlled substance may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 28, 2009.

     Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-26002 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.